首页> 外文OA文献 >Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
【2h】

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

机译:人类B细胞淋巴瘤中组蛋白甲基转移酶EZH2中A677的突变促进了赖氨酸27(H3K27)上组蛋白H3的超三甲基化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Trimethylation of histone H3 on lysine 27 (H3K27me3) is a repressive posttranslational modification mediated by the histone methyltransferase EZH2. EZH2 is a component of the polycomb repressive complex 2 and is overexpressed in many cancers. In B-cell lymphomas, its substrate preference is frequently altered through somatic mutation of the EZH2 Y641 residue. Herein, we identify mutation of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens. Similar to Y641 mutant cell lines, an A677G mutant cell line revealed aberrantly elevated H3K27me3 and decreased monomethylated H3K27 (H3K27me1) and dimethylated H3K27 (H3K27me2). A677G EZH2 possessed catalytic activity with a substrate specificity that was distinct from those of both WT EZH2 and Y641 mutants. Whereas WT EZH2 displayed a preference for substrates with less methylation [unmethylated H3K27 (H3K27me0):me1:me2 kcat/Km ratio = 9:6:1] and Y641 mutants preferred substrates with greater methylation (H3K27me0:me1:me2 kcat/Km ratio = 1:2:13), the A677G EZH2 demonstrated nearly equal efficiency for all three substrates (H3K27me0:me1:me2 kcat/Km ratio = 1.1:0.6:1). When transiently expressed in cells, A677G EZH2, but not WT EZH2, increased global H3K27me3 and decreased H3K27me2. Structural modeling of WT and mutant EZH2 suggested that the A677G mutation acquires the ability to methylate H3K27me2 through enlargement of the lysine tunnel while preserving activity with H3K27me0/me1 substrates through retention of the Y641 residue that is crucial for orientation of these smaller substrates. This mutation highlights the interplay between Y641 and A677 residues in the substrate specificity of EZH2 and identifies another lymphoma patient population that harbors an activating mutation of EZH2.
机译:赖氨酸27(H3K27me3)上的组蛋白H3的三甲基化是由组蛋白甲基转移酶EZH2介导的抑制性翻译后修饰。 EZH2是多梳抑制复合物2的组成部分,在许多癌症中均过表达。在B细胞淋巴瘤中,其底物偏好经常通过EZH2 Y641残基的体细胞突变而改变。在这里,我们确定淋巴瘤细胞系和原发性肿瘤标本中的EZH2 A677突变为甘氨酸(A677G)。与Y641突变细胞系相似,A677G突变细胞系显示H3K27me3异常升高,而单甲基化H3K27(H3K27me1)和二甲基化H3K27(H3K27me2)降低。 A677G EZH2具有催化活性,底物特异性不同于WT EZH2和Y641突变体。而WT EZH2偏爱甲基化程度较低的底物[未甲基化的H3K27(H3K27me0):me1:me2 kcat / Km比= 9:6:1],而Y641突变体则首选甲基化程度更高的底物(H3K27me0:me1:me2 kcat / Km比= 1:2:13),A677G EZH2对所有三种基材均表现出几乎相同的效率(H3K27me0:me1:me2 kcat / Km比= 1.1:0.6:1)。当在细胞中瞬时表达时,A677G EZH2而非WT EZH2会增加整体H3K27me3并降低H3K27me2。 WT和突变体EZH2的结构模型表明,A677G突变通过扩大赖氨酸通道获得甲基化H3K27me2的能力,同时通过保留Y641残基保留H3K27me0 / me1底物的活性,这对于这些较小的底物的定向至关重要。该突变突出显示了EZH2底物特异性中Y641和A677残基之间的相互作用,并鉴定了另一个携带EZH2激活突变的淋巴瘤患者人群。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号